µå·¯±×ÀÎÆ÷¸ÞÀÎ
 

»óº´Äڵ忡 µû¸¥ »óº´¸íÀ» È®ÀÎ ÇϽǼö ÀÖ½À´Ï´Ù.  
»óº´ÄÚµå ÇÑ±Û»óº´¸í ¿µ¹®»óº´¸í
Y491 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¸ð³ë¾Æ¹Î-¿Á½Ãµ¥À̽º ¾ïÁ¦¼º Ç׿ì¿ïÁ¦ Monoamine-oxidase-inhibitor antidepressants causing adverse effects in therapeutic use
Y492 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ ¹× »ó¼¼ºÒ¸íÀÇ Ç׿ì¿ïÁ¦ Other and unspecified antidepressants causing adverse effects in therapeutic use
Y493 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Æä³ëµð¾ÆÁø Ç×Á¤½Åº´ ¾àÁ¦ ¹× ½Å°æÀÌ¿ÏÁ¦ Phenothiazine antipsychotics and neuroleptics causing adverse effects in therapeutic use
Y494 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ºÎƼ·ÎÆä³í ¹× Áö¿Á»êƾ ½Å°æÀÌ¿ÏÁ¦ Butyrophenone and thioxanthene neuroleptics causing adverse effects in therapeutic use
Y495 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ Ç×Á¤½Åº´¾àÁ¦ ¹× ½Å°æÀÌ¿ÏÁ¦ Other antipsychotics and neuroleptics causing adverse effects in therapeutic use
Y496 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ȯ°¢Á¦ Psychodysleptics [hallucinogens] causing adverse effects in therapeutic use
Y497 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ³²¿ëÀÇ ÀáÀ缺ÀÌ ÀÖ´Â Á¤½ÅÈïºÐÁ¦ Psycostimulants with abuse potential causing adverse effects in therapeutic use
Y498 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ±âŸ Á¤½ÅÀÛ¿ë¾à¹° Other psychotropic drugs, NEC causing adverse effects in therapeutic use
Y499 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â »ó¼¼ºÒ¸íÀÇ Á¤½ÅÀÛ¿ë¾à¹° Psychotropic drug, unspecified causing adverse effects in therapeutic use
Y50 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ÁßÃ߽Űæ°èÅë ÈïºÐÁ¦ Central nervous system stimulants, NEC causing adverse effects in therapeutic use
Y500 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â °¢¼ºÁ¦ Analeptics causing adverse effects in therapeutic use
Y501 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¾ÆÆí¼ö¿ëü±æÇ×Á¦ Opioid reactor antagonists causing adverse effects in therapeutic use
Y502 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ¸ÞÆ¿»êƾ Methylxanthines, NEC causing adverse effects in therapeutic use
Y502 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ä«ÆäÀÎ Caffeine causing adverse effects in therapeutic use
Y508 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ ÁßÃ߽Űæ°èÅë ÈïºÐÁ¦ Other central nervous system stimulants causing adverse effects in therapeutic use
Y509 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â »ó¼¼ºÒ¸íÀÇ ÁßÃ߽Űæ°èÅë ÈïºÐÁ¦ Central nervous system stimulant, unspecified causing adverse effects in therapeutic use
Y51 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀÏÂ÷ÀûÀ¸·Î ÀÚÀ²½Å°æ°èÅë¿¡ ÀÛ¿ëÇÏ´Â ¾àÁ¦ Drugs primarily affecting the autonomic nervous system causing adverse effects in therapeutic use
Y510 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç×Äݸ°¿¡½ºÆ®·¹À̽ºÁ¦ Anticholinesterase agents causing adverse effects in therapeutic use
Y511 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ ºÎ±³°¨½Å°æÀÛ¿ëÁ¦[Äݸ°Á¦] Other parasympathomimetics[cholinergics] causing adverse effects in therapeutic use
Y512 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ½Å°æÀýÂ÷´ÜÁ¦ Ganglionic blocking drugs, NEC causing adverse effects in therapeutic use
3871  3872  3873  3874  3875  3876  3877  3878  [3879] 3880